肾移植状态对华法林剂量、抗凝控制及出血风险的影响
基于华法林药物基因组学前瞻性队列,比较65例肾移植受者与1630例非移植患者。肾移植受者华法林所需剂量约低20%(4.7 vs 5.6 mg/日,p=0.0005),治疗范围内时间百分比相似,大出血风险较高(HR 2.1,p=0.0081),但校正肾功能、临床及遗传因素后差异无统计学意义。
要点
- 肾移植受者起始华法林所需剂量约低20%,需更密切监测。
- 两组抗凝控制质量(PTTR≥60%比例)均低且相似。
- 肾移植受者大出血风险粗分析较高,但校正后无统计学差异。
核心结论
- 肾移植受者起始华法林需要更低剂量和更密切监测以优化抗凝治疗。
研究设计与样本
- 华法林药物基因组学队列的前瞻性分析,随访于两个抗凝门诊。
- 纳入年龄≥20岁、目标INR 2-3的首次华法林使用者,肾移植受者65例,非移植患者1630例。
主要发现
- 肾移植受者华法林剂量约低20%(4.7 vs 5.6 mg/日,p=0.0005)。
- 遗传变异对两组剂量的影响相似。
- 平均PTTR在肾移植受者与非移植患者间相似。
- 达到良好抗凝控制(PTTR≥60%)的比例在两组均低且相似。
- 肾移植受者大出血风险较高(HR 2.1,p=0.0081),但校正肾功能、临床及遗传因素后差异无统计学意义。
临床怎么用
- 肾移植受者起始华法林时应考虑约20%的剂量减低。
- 对肾移植受者进行更密切的抗凝监测。
局限性
- 需更多研究确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: To assess whether warfarin dose requirement, anticoagulation control, and risk of hemorrhage differ in kidney transplant recipients (KTRs) compared with patients without kidney transplants (non-KTRs). DESIGN: Analysis of data from the Warfarin Pharmacogenetics Cohort, a prospective cohort of first-time warfarin users followed at two anticoagulation clinics. SETTING: Two outpatient anticoagulation clinics at two large, academic, tertiary care hospitals. PATIENTS: Adults aged 20 years or older starting warfarin for anticoagulation with a therapeutic international normalized ratio (INR) goal of 2-3 who were KTRs (n=65) or non-KTRs (n=1630). MEASUREMENTS AND MAIN RESULTS: Warfarin dose requirement, anticoagulation control, and risk of hemorrhage were assessed in each group. KTRs required an approximately 20% lower warfarin dose (4.7 vs 5.6 mg/day, p=0.0005) compared with non-KTRs. Genetic variants had similar effects on dose in both groups. Mean percentage of time in therapeutic range (PTTR) was similar among KTRs and non-KTRs. Although the proportion of patients achieving good anticoagulation control (PTTR ≥ 60%) was low in both groups, it was similar among KTRs and non-KTRs. KTRs had a higher risk of major hemorrhage (hazard ratio 2.1, p=0.0081), but this difference was not statistically significant after controlling for kidney function, clinical, and genetic factors. CONCLUSION: KTRs initiating warfarin require lower doses and closer monitoring to optimize anticoagulation therapy. Additional studies are needed to confirm these findings.
引用
- Yanik MV, Irvin MR, Beasley TM, et al. Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy. 2017. PMID: 28949423. doi:10.1002/phar.2032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。